The immunoSEQ assay was used on 11 specimens (unsorted MILs, IFNg-capture- sorted tumor antigen-specific CD4+ and CD8+ T cells, and blood and BM collected pre-treatment and 60, 180 and 360 days post-infusion) from 6 patients (3 clinical responders who achieved a CR and 3 non-responders whose disease progressed) from the Phase I study. Here, CD4 is linked to neoplasm.